|
1
|
Wake MS and Watson CJ: STAT3 the
oncogene-still eluding therapy? FEBS J. 282:2600–2611. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhao C, Li H, Lin HJ, Yang S, Lin J and
Liang G: Feedback activation of STAT3 as a cancer drug-resistance
mechanism. Trends Pharmacol Sci. 37:47–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bromberg JF, Wrzeszczynska MH, Devgan G,
Zhao Y, Pestell RG, Albanese C and Darnell JE Jr: Stat3 as an
oncogene. Cell. 98:295–303. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Srivastava J and DiGiovanni J:
Non-canonical Stat3 signaling in cancer. Mol Carcinog.
55:1889–1898. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
You L, Wang Z, Li H, Shou J, Jing Z, Xie
J, Sui X, Pan H and Han W: The role of STAT3 in autophagy.
Autophagy. 11:729–739. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu H, Lee H, Herrmann A, Buettner R and
Jove R: Revisiting STAT3 signaling in cancer: New and unexpected
biological functions. Nat Rev Cancer. 14:736–746. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carbognin E, Betto RM, Soriano ME, Smith
AG and Martello G: Stat3 promotes mitochondrial transcription and
oxidative respiration during maintenance and induction of naive
pluripotency. EMBO J. 35:618–634. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Erlich TH, Yagil Z, Kay G, Peretz A,
Migalovich-Sheikhet H, Tshori S, Nechushtan H, Levi-Schaffer F,
Saada A and Razin E: Mitochondrial STAT3 plays a major role in
IgE-antigen-mediated mast cell exocytosis. J Allergy Clin Immunol.
134:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Park JK, Hong R, Kim KJ, Lee TB and Lim
SC: Significance of p-STAT3 expression in human colorectal
adenocarcinoma. Oncol Rep. 20:597–604. 2008.PubMed/NCBI
|
|
10
|
Ferguson SD, Srinivasan VM and Heimberger
AB: The role of STAT3 in tumor-mediated immune suppression. J
Neurooncol. 123:385–394. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Furtek SL, Backos DS, Matheson CJ and
Reigan P: Strategies and approaches of targeting STAT3 for cancer
treatment. ACS Chem Biol. 11:308–318. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chai EZ, Shanmugam MK, Arfuso F,
Dharmarajan A, Wang C, Kumar AP, Samy RP, Lim LH, Wang L, Goh BC,
et al: Targeting transcription factor STAT3 for cancer prevention
and therapy. Pharmacol Ther. 162:86–97. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao Y, Chen S, Gou WF, Niu ZF, Zhao S,
Xiao LJ, Takano Y and Zheng HC: The role of EMMPRIN expression in
ovarian epithelial carcinomas. Cell Cycle. 12:2899–2913. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lassmann S, Schuster I, Walch A, Göbel H,
Jütting U, Makowiec F, Hopt U and Werner M: STAT3 mRNA and protein
expression in colorectal cancer: Effects on STAT3-inducible targets
linked to cell survival and proliferation. J Clin Pathol.
60:173–179. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma XT, Wang S, Ye YJ, Du RY, Cui ZR and
Somsouk M: Constitutive activation of Stat3 signaling pathway in
human colorectal carcinoma. World J Gastroentero. 10:1569–1573.
2004. View Article : Google Scholar
|
|
16
|
Xue X, Jungles K, Onder G, Samhoun J,
Győrffy B and Hardiman KM: HIF-3α1 promotes colorectal tumor cell
growth by activation of JAK-STAT3 signaling. Oncotarget.
7:11567–11579. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zou F, Mao R, Yang L, Lin S, Lei K, Zheng
Y, Ding Y, Zhang P, Cai G, Liang X and Liu J: Targeted deletion of
miR-139-5p activates MAPK, NF-κB and STAT3 signaling and promotes
intestinal inflammation and colorectal cancer. FEBS J.
283:1438–1452. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yao C, Su L, Shan J, Zhu C, Liu L, Liu C,
Xu Y, Yang Z, Bian X, Shao J, et al: IGF/STAT3/NANOG/Slug signaling
axis simultaneously controls epithelial-mesenchymal transition and
stemness maintenance in colorectal cancer. Stem Cells. 34:820–831.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu H, Ren G, Wang T, Chen Y, Gong C, Bai
Y, Wang B, Qi H, Shen J, Zhu L, et al: Aberrantly expressed Fra-1
by IL-6/STAT3 transactivation promotes colorectal cancer
aggressiveness through epithelial-mesenchymal transition.
Carcinogenesis. 36:459–468. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Spitzner M, Roesler B, Bielfeld C, Emons
G, Gaedcke J, Wolff HA, Rave-Fränk M, Kramer F, Beissbarth T, Kitz
J, et al: STAT3 inhibition sensitizes colorectal cancer to
chemoradiotherapy in vitro and in vivo. Int J Cancer. 134:997–1007.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fan LC, Teng HW, Shiau CW, Tai WT, Hung
MH, Yang SH, Jiang JK and Chen KF: Pharmacological targeting
SHP-1-STAT3 signaling is a promising therapeutic approach for the
treatment of colorectal cancer. Neoplasia. 17:687–696. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xiong H, Chen ZF, Liang QC, Du W, Chen HM,
Su WY, Chen GQ, Han ZG and Fang JY: Inhibition of DNA
methyltransferase induces G2 cell cycle arrest and apoptosis in
human colorectal cancer cells via inhibition of JAK2/STAT3/STAT5
signalling. J Cell Mol Med. 13:3668–3679. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao B and Dong AS: MiR-874 inhibits cell
growth and induces apoptosis by targeting STAT3 in human colorectal
cancer cells. Eur Rev Med Pharmacol Sci. 20:269–277.
2016.PubMed/NCBI
|
|
24
|
Zhang J, Lu Y, Yue X, Li H, Luo X, Wang Y,
Wang K and Wan J: MiR-124 suppresses growth of human colorectal
cancer by inhibiting STAT3. PLoS One. 8:e703002013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu F, Zhang T, Zou S, Jiang B and Hua D:
B7-H3 promotes cell migration andinvasion through the
Jak2/Stat3/MMP9 signaling pathway in colorectal cancer. Mol Med
Rep. 12:5455–5460. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhang T, Jiang B, Zou ST, Liu F and Hua D:
Overexpression of B7-H3 augmentsanti-apoptosis of colorectal cancer
cells by Jak2-STAT3. World J Gastroenterol. 21:1804–1813. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wei X, Wang G, Li W, Hu X, Huang Q, Xu K,
Lou W, Wu J, Liang C, Lou Q, et al: Activation of the JAK-STAT3
pathway is associated with the growth of colorectal carcinoma
cells. Oncol Rep. 31:335–341. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Qian WF, Guan WX, Gao Y, Tan JF, Qiao ZM,
Huang H and Xia CL: Inhibition of STAT3 by RNA interference
suppresses angiogenesis in colorectal carcinoma. Braz J Med Biol
Res. 44:1222–1230. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cascio S, Ferla R, D'Andrea A, Gerbino A,
Bazan V, Surmacz E and Russo A: Expression of angiogenic
regulators, VEGF and leptin, is regulated by the EGF/PI3K/STAT3
pathway in colorectal cancer cells. J Cell Physiol. 221:189–194.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Soleimanpour E and Babaei E: Survivin as a
potential target for cancer therapy. Asian Pac J Cancer Prev.
16:6187–6191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xiao LJ, Zhao S, Zhao EH, Zheng X, Gou WF,
Takano Y and Zheng HC: Clinicopathological and prognostic
significance of Ki-67, caspase-3 and p53 expression in gastric
carcinomas. Oncol Lett. 6:1277–1284. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang X, Simpson ER and Brown KA: p53:
Protection against tumor growth beyond effects on cell cycle and
apoptosis. Cancer Res. 75:5001–5007. 2015. View Article : Google Scholar : PubMed/NCBI
|
